Full-Time
Operational Excellence Manager
Industrial Site
Vetoquinol
1,001-5,000 employees
Develops and markets veterinary medicines
No salary listed
Lure, France
In Person
Occasional travel required.
Bachelor's
 Business & Strategy (1) |
|---|
Get referred to Vetoquinol
See people who can refer or advise you
- A university or Grande École diploma in a business-school or engineering-school discipline is required.
- Lean or Six Sigma Black Belt certification is required.
- At least five years of experience in a continuous-improvement role at an industrial site is required.
- A good understanding of financial-results forecasting, financial analysis, and cost calculation is required.
- A good understanding of commercial and technical matters, including digital technology, is required.
- Strong computer skills in Excel, enterprise resource planning systems, and Word are required.
- Understanding of core industrial processes, including production, quality, supply chain, warehousing, and logistics, is required.
- English proficiency at B2 level is required.
- The candidate must be able to work in multicultural teams.
- The candidate must demonstrate results orientation, change management and support skills, and influence.
- Identify situations that could affect the physical and psychological well-being of team members, implement preventive actions, and mobilize necessary resources.
- Follow and enforce applicable safety rules, implement corrective actions, participate in safety audits, optimize energy consumption, and support environmental-protection actions.
- Manage the activity of the team, create the conditions for its success, contribute to team cohesion, and encourage cross-functional collaboration.
- Ensure that team members have the knowledge and skills needed to achieve assigned missions and objectives.
- Lead a site-effectiveness diagnosis against local and Group expectations.
- Define, with area managers, a roadmap for improving performance measured by key performance indicators and specific objectives.
- Ensure that Group operational-excellence expectations are addressed locally in collaboration with the plant director and STMEO manager.
- Support operational teams and help define corrective actions when objectives are not achieved.
- Ensure updates to routings, bills of materials, and technical methods, and lead the process for analyzing production deviations from routings and implementing necessary actions.
- Ensure the implementation and effectiveness of operational-excellence actions and their actual contribution to performance measured by key performance indicators.
- Build, organize, train, coordinate, coach, and continuously support the operational-excellence network.
- Ensure that network members, managers, and employees have the knowledge and skills needed to accomplish assigned missions and objectives, and propose development actions when necessary.
- Use a systemic approach to make processes and their performance-improvement potential visible.
- Improve process effectiveness and ensure that all interconnections operate effectively.
- Participate in designing new processes to achieve the best performance.
- Ensure the proper local implementation of Group operational-excellence standards.
- Monitor new methodologies and share them with the Group network.
- Share local experience, learn from other sites, and implement their best practices.
- Contribute to defining Group standards and Group initiatives.
- Collaborate with Group operational-excellence leadership, operational-excellence managers at other industrial sites, the plant director's direct reports, and finance, human resources, operations, supply-chain, quality, safety, and product-development leaders.
- Travel occasionally.
Vetoquinol is a global animal health company that develops and markets medicines and health products for pets and livestock. Its products are used to treat diseases, prevent illness, and support animal well-being, distributed through a network of subsidiaries and partners in about 24 direct countries with products available in around 100 countries. Core operations include research, development, and commercialisation of veterinary pharmaceuticals and health solutions for both companion and farm animals. What sets Vetoquinol apart is its long family-led history and steady international expansion, including an IPO in 2006 to accelerate growth, which has helped it build a widespread, multi-country presence. The company’s goal is to improve animal health globally by bringing effective veterinary products to markets around the world and expanding access through direct operations and partnerships.
Company Size
1,001-5,000
Company Stage
IPO
Headquarters
Paris, France
Founded
1933
Get referred to Vetoquinol
See people who can refer or advise you
Simplify's Take
What believers are saying
- Q1 2026 U.S. sales rose 15.6% constant-currency, showing strong American demand.
- 2025 EBIT before amortization reached €91.5M and net cash hit €205.8M.
- Essential Products grew 4.1% in 2025, and management is preparing 2027 launches.
What critics are saying
- 2025 recalls for FOLLTROPIN in the U.S., UK, and Canada damaged quality credibility.
- Q1 2026 sales fell 4.3% reported, with €5.2M currency drag hitting U.S. and India.
- The 2027 launch dependence makes 2026 a transition year if pipeline timing slips.
What makes Vetoquinol unique
- Vetoquinol’s 2025 Essential Products reached €334.5M, 64% of sales, strengthening mix.
- It internalized parasiticide manufacturing in 2025, improving control over critical supply.
- Command Centre ACT extends VetImpress, bundling software, compliance, and revenue management for practices.
Help us improve and share your feedback! Did you find this helpful?
Benefits
Health Insurance
Disability Insurance
Paid Vacation
Commuter Benefits
Wellness Program
Professional Development Budget
Training Programs
Growth & Insights and Company News
6 month growth
↑ 2%1 year growth
↑ 2%2 year growth
↑ 2%Vetoquinol, a French animal health company, reported first-quarter 2026 sales of €125 million, down 4.3% on a reported basis but flat at constant exchange rates. Excluding currency effects and a product line simplification programme, sales increased 1.2% year-on-year. Exchange rate headwinds reached €5.2 million, primarily affecting the United States and India. The product line simplification programme impacted sales by €1.7 million. Essential products sales totalled €83 million, stable at constant exchange rates, whilst complementary products grew, driven by strong US performance. US sales rose 15.6% at constant exchange rates to €28 million. Companion animal products represented 71% of sales at €93 million, whilst farm animal products totalled €38 million. The company described 2026 as a transition year ahead of new product launches in 2027.
Vetoquinol launches Command Centre ACT. The platform creates 'clear accountability' and eases the administrative burden of tracking vaccinations and farm visits. A veterinary pharmaceutical company has launched a dashboard to help ease administrative burdens on farm and mixed practices and drive revenue growth and clinical compliance. Vetoquinol has launched Command Centre ACT, a dashboard extension for its VetImpress data management platform designed for clinical directors and business development staff. The extension is said to draw on practices' data stored within VetImpress or their practice management system to identify revenue opportunities and compliance gaps. Based on analysis using leptospirosis, bovine viral diarrhoea and infectious bovine rhinotracheitis, Vetoquinol estimates that in dairy herds alone, missed vaccination doses, lapsed vaccinations and unvaccinated herds demonstrate an opportunity of around £2,877 annually per farm vet. 'Strategic approach' As well as optimising vaccine scheduling and compliance, Command Centre ACT is said to address regulatory requirements such as Veterinary Medicines Requirements "animals under care" guidelines, automatically flagging farms that are due visits to visually inspect livestock. Vetoquinol product manager Andy Paine said: "The dashboard's name reflects its strategic approach to practice management. "Command Centre ACT enables the user to identify farms requiring attention and assign specific follow-up actions to individual vets through the VetImpress diary and tasks system, creating clear accountability whilst maintaining clinical focus. "We're ultimately selling accountability, but we're striking the right balance between management oversight and clinical autonomy." Work and well being 20 Apr 2026 Small animal 3 Mar 2026
Vetoquinol, a French veterinary pharmaceutical company, reported annual sales of €526 million for 2025, up 0.2% at constant exchange rates but down 2.5% on a reported basis. The company faced historically high negative currency impacts of €14.8 million and a €9.7 million decline from simplifying its Complementary product ranges. Essential Products sales reached €334.5 million, growing 4.1% at constant exchange rates, driven by a strong fourth quarter increase of 8.0%. The company completed transferring manufacturing of its parasiticide range to its own facilities. Essential Products now represent 64% of total sales, up from 61% in 2024. Companion animal products accounted for 72% of sales at €377 million, whilst farm animal products represented 28% at €149 million.
Vetoquinol released the first fluorescent light therapy system for dogs and cats—Phovia—to help accelerate natural skin regeneration.
Mongeau joins Vetoquinol from Nikon Optical, where she most recently served as CEO for Canada and the USA.